By Deb Borfitz
As of this year, Eli Lilly and Company is converting to a new operating model designed to streamline drug development and better “capture the value” of a record-setting number of new medicines in its pipeline…read more
Once again, Tessella is proudly sponsoring this years’ Bio-IT Best Practice Awards 2010, being held at the World Trade Centre, Boston, MA, USA on April 21, 2010 in conjunction with Bio-IT’s World Conference and Expo 2010.
Established in 2003, the award programme recognizes teams in industry and academia for their outstanding innovations and excellence in the enabling [...]
By Parloop A Bhatt
Traditional clinical trials, in which a protocol is designed according to certain assumptions and strictly followed throughout the study, have numerous inefficiencies. Because there is no opportunity for researchers to adapt a protocol to reflect their increasing understanding of a drug as a trial progresses, the outcome may be inconclusive if the [...]
Long known for its scientific software delivery expertise and technical staffing capability, Tessella now dedicates 100 consultants (30% of its business) to life sciences…read more
Kevin Davies, Editor-in-Chief, Bio-IT and Tessella’s Dr Andrew Chadwick, Principle Consultant, Life Sciences and Health Care discuss Translational Medicine. Listen to this podcast and learn about:
Effective, ethical approaches to trial design that harness incompletely validated predictive and prognostic biomarkers
Ways to improve the value of image information and other rich data
The tradeoffs to expect in using [...]
Two Drug Information Journal articles on planning and executing response adaptive clinical trials state savings of 2 to 5 months and $1 million to $14 million when using adaptive trials versus using more traditional designs. The Journal’s articles are available on-line: article one - The Process page 710 and article two - Case Studies page 725
- Efficacy and safety data supports advancement to a comparative trial as a strategy to support registration -
Read more pdf
Tessella are proudly sponsoring SMi’s 4th annual conference in Adaptive Designs in Clinical Drug Development. The conference and workshop are being held on February 3rd – 4th 2010, at the Crowne Plaza Hotel, St James, London, UK.
Tessella’s Tom Parke, head of clinical trial solutions, will be presenting Adaptive Trial Design for Oncology Trials on Wednesday [...]
Long known for its scientific software delivery expertise and technical staffing capability, Tessella is mounting a push to climb higher up the consultancy ladder…read more
By Tom Parke
The US Food and Drug Administration (FDA) end-of-Phase 2a (EOP2A) meeting guidance issued on the September 2009 emphasises the value of the greater use of trial simulation and alternative design strategies in the clinical trials design process. The FDA’s primary purpose of an EOP2A meeting is to select the dosing regime and design [...]
